[STUDY_ID_REMOVED]  
 
Study ID: UBR‐MD‐02 
 
Title:  A Phase 3, Multicenter,  Randomized,  Double‐Blind, Placebo‐Controlled  Single Attack Study to 
Evaluate the Efficacy, Safety,  and Tolerability  of Oral Ubrogepant  in the Acute Treatment  of Migraine 
 
Protocol Amendment  3 Date: 19 May 2017 
 
 
 
Allergan Confidential Protocol UBR -MD-02 Amendment 3
1Title Page
ALLERGAN – CONFIDENTIAL
The following contains confidential, proprietary  information 
which is the propert y of Allergan
A PHASE 3, MUL TICENTER, RANDOMIZED, DOUBLE -BLIND, PLACEBO -
CONTROLLED SINGLE ATTACK STUDY  TO EVALUA TE THE EFFICACY , 
SAFETY , AND TOLERABILITY  OF ORAL  UBROGEP ANT 
IN THE ACUTE TREA TMENT  OF M IGRAINE
Protocol Number:  UBR -MD-02 Amendment 3
Phase: 3
Name of Investigational Product: Ubrogepant
Sponsor: Allergan Pharmaceuticals 
International Limited
Clonshaugh Industrial Es tate
Coolock
Dublin 17
IrelandAuthorized US Agent
Allergan Sales, LLC
2525 Dupont Drive
Irvine, California USA   92612
Emergency Telephone Number(s): Refer to the Study Contacts Sheet
Serious Adverse Event Reporting 
Fax Number:
Allergan Medical Monitor
Contact Information:Please see Study Contact sSheet
Allergan Signatory:
Original Protocol Date: 19 May 2016
Protocol Amendment 1 Date 09 Jun 2016
Protocol Amendment 2 Date 04 Nov 2016
Protocol Amendment 3 Date: 19May 2017
 UBR-MD-02
1

Allergan Confidential Protocol UBR -MD-02 Amendment 3
2The following information can be found on FDA Form 1572 and/or study  contacts page:  
Emergency T elephone Numbers; name, address, and statement of qualifications of each 
investigator; name of each subinvestigator working under the supervision of the investigator; 
name and address of the research facil ities to be used; name and address of each reviewing 
IRB; US 21 CFR 312.23 section 6(iii)b.
 UBR-MD-02
2
Allergan Confidential Protocol UBR -MD-02 Amendment 3
3INVESTIGA TOR SIGNA TURE PAGE
INVESTIGATOR:
I agree to:
Implement and conduct this study diligentl y and in strict compliance with the protocol, 
good clinical practices and all applicable laws and regulations.
Maintain all information supplied by  Allergan in confidence and, when this 
information is submitted to an Institutional Review Board (IRB), Independent Ethics 
Committee (I EC) or another group, it will be submitted with a designation that the 
material is confidential.
Ensure that all persons assisting with the trial are adequatel y informed about the 
protocol , the investigational product(s), and their trial- related duties and functions.
I have read this protocol in its entirety  and I agree to all aspects.
Investigator Printed Name Signature Date
 UBR-MD-02
3
Allergan Confidential Protocol UBR -MD-02 Amendment 3
4Table of Contents
Title Page .................................................................................................................................. 1
Table of Contents ...................................................................................................................... 4
List of T ables ............................................................................................................................. 7
List of Figures ........................................................................................................................... 7
Protocol Summa ry.................................................................................................................... 8
1. Background and Clinical Rationale ............................................................................ 15
2. Study  Objectives and Clinical Hy potheses ................................................................. 17
2.1 Study  Objectives ............................................................................................. 17
2.2 Clinical Hy potheses ........................................................................................ 17
3. Study  Design ............................................................................................................... 17
3.1 Adjudication Committee and Data Safet y Monitoring Board ........................ 18
4. Study  Population and Entry  Criteria ........................................................................... 19
4.1 Number of Patients ................................
......................................................... 19
4.2 Study  Population Characteristics .................................................................... 19
4.3 Inclusion Criteria
............................................................................................ 19
4.4 Exclusion Criteria ................................
........................................................... 20
4.5 Permissible and Prohibited Medications/Treatments...................................... 23
4.5.1 Permissible Medications/Treatments .................................................. 23
4.5.1.1 Acute Treatment /Rescue Medication ..................................
24
4.5.1.2 Definition of Females of (Non -)Childbearing Potential 
and/or Acceptable Contraceptive Methods .......................... 24
4.5.2 Prohibited Medications/Treatments .................................................... 25
4.5.3 Special Diet or Activities ................................
.................................... 26
5. Study  Treatments ........................................................................................................ 26
5.1 Study Treatments and Formulations ............................................................... 26
5.2 Control Treatment ........................................................................................... 26
5.3 Methods for Masking/Blinding ................................ ................................ ....... 26
5.4 Treatment Allocation Ratio ................................ ................ 26
5.5 Method for Assignment to Treatment 
Groups/Randomization/ ............................................................. 27
5.6 Treatment Regimen and Dosing ..................................................................... 28
5.6.1 Treatment Administration ...................................................................
28
5.6.3 Optional Second Dose and Rescue Medication .................................. 29
5.7 Storage of Investigational Products/Treatments ............................................. 30
 UBR-MD-02
4

Allergan Confidential Protocol UBR -MD-02 Amendment 3
56. Response Measures and Summary of Data Collection Methods ................................ 30
6.1 Efficacy Measures ................................................................ ........................... 30
6.6 Other Study  Supplies ...................................................................................... 37
6.7 Summary  of Methods of Data Collection ....................................................... 38
7. Statistical Procedures .................................................................................................. 38
7.1 Analy sis Populations ....................................................................................... 38
7.1.1 Modified Intent -to-treat Population .................................................... 38
7.1.2 Safety  Population ................................................................................ 38
7.2 Collection and Derivation of Efficacy  Assessments ....................................... 39
7.2.1 Primary  Efficacy  Variables ................................................................. 39
7.2.2 Secondary  Efficacy  Variables ............................................................. 39
7.3 Hypothesis and Methods of Anal ysis............................................................. 41
7.3.1 Efficacy  Analyses............................................................................... 42
7.3.1.1 Primary  Efficacy  Anal yses.................................................. 42
7.3.1.2 Secondary  Efficacy  Analy ses.............................................. 42
7.3.2 Pharmacokinetic Analy ses.................................................................. 45
7.6 Interim Anal yses................................ ................................ ............................. 51
8. Patient Entry  Procedures ................................ ................................ ............................. 51
8.1.1 Overview of Entry  Procedures ................................ ............................ 51
 UBR-MD-02
5

Allergan Confidential Protocol UBR -MD-02 Amendment 3
68.1.2 Informed Consent and Patient Privacy ............................................... 51
8.2 Washout I ntervals/Run -In............................................................................... 52
8.3 Procedures for Final Study  Entry .................................................................... 52
8.5 Instructions for the Patients ............................................................................ 58
8.6 Unscheduled Visits ......................................................................................... 58
8.7 Compliance with Protocol............................................................................... 58
8.8 Early Discontinuation of Patients ................................
................................... 59
8.9 Withdrawal Criteria ........................................................................................
60
8.11 Study  Termination ................................ ................................ .......................... 60
9. Adverse Events ........................................................................................................... 60
9.1 Definitions.......................................................................................................
60
9.1.1 Adverse Event ..................................................................................... 60
9.1.2 Serious Adverse Event ........................................................................ 61
9.1.3 Severity ............................................................................................... 62
9.1.4 Relationship to Study  Drug or Stud y Procedure ................................. 62
9.2 Procedures for Reporting Adverse Events ...................................................... 62
9.3 Procedures for Reporting a Serious Adverse Event ........................................ 62
9.4 Exposure to I nvestigat ional Product during Pregnancy .................................. 63
9.7 Procedures for Unmasking of Investigational Product ................................... 65
10. Administrative I tems ................................................................................................... 66
10.1 Protection of Human Patients ......................................................................... 66
10.1.1 Compliance With I nformed Consent Regulations (US 21 CFR Part 
50) and Relevant Country  Regulations ............................................... 66
10.1.2 Compliance With I RB or I EC Regulations ................................ ......... 66
10.1.3 Compliance With Good Clinical Practice ................................ ........... 66
10.1.4 Compliance With Electronic Records; Electronic Signatures 
Regulations (US 21 CFR Part 11)....................................................... 66
10.2 Changes to the Protocol .................................................................................. 66
10.3 Patient Confidentiality .................................................................................... 67
10.3.1 Patient Privacy ................................ ................................ .................... 67
10.4 Documentation ................................ ................................ ................................ 67
10.4.1 Source Documents ................................ ................................ .............. 67
10.4.2 Electronic Case Report Form Completion ................................ .......... 68
10.4.3 Study  Summary ................................ ................................ ................... 68
10.4.4 Retention of Documentation ................................ ............................... 69
 UBR-MD-02
6

Allergan Confidential Protocol UBR -MD-02 Amendment 3
710.5 Labeling, Packaging, and Return or Disposal of Investigational 
Products/Treatments ................................................................ ....................... 69
10.5.1 Labeling/Packaging ............................................................................. 69
10.5.2 Clinical Supply  Inventory ................................ ................................ ... 69
10.5.3 Return or Disposal of Investigational Products/Treatments and/or 
Supplies ............................................................................................... 70
10.6 Monitoring b y the Sponsor ............................................................................. 70
10.7 Handling of Biological Specimens/Samples................................................... 70
10.8 Publications ................................
..................................................................... 71
10.9 Coordinating Investigator ...............................................................................
71
11. References ................................................................................................................... 72
12. Attachments ................................................................................................................ 74
12.1 Examination Procedures, Tests, Equipment, and Techniques ........................ 74
12.1.1 International Classification of Headache Disorders, 3rdEdition, 
Beta Version ........................................................................................
74
12.2 Examples of Prohibited Medications .............................................................. 89
12.3 Glossary  of Abbreviations .............................................................................. 92
12.4 Protocol Amendment 1 Summary ................................................................... 94
12.5 Protocol Amendment 2 Summary ................................................................... 97
12.6 Protocol Amendment 3 Summary ................................................................. 103
List of Tables
Table 2 Treatments Administered for Initial and Optional Second Dose.................... 28
Table 3 Clinical L aboratory  Parameters ......................................................................
35
Table 4 Assumed Response Rates and Estimated Power for Primary  and Secondary  
Efficacy  Endpoints .......................................................................................... 51
List of Figur es
 UBR-MD-02
7

Allergan Confidential Protocol UBR -MD-02 Amendment 3
8Protocol Summary
Study Compound(s):  Ubrogepant
Phase:  3
Study Objective:  To evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant ( 25mg and 50mg) 
compared to placebo for the acute treatment of a single migraine attack
Clinical Hypotheses:
1.  At least 1 ubrogepant dose is superior to placebo in the acute treatment of migraine .
2.  Ubrogepant is safe and tolerable.
Study Design
Structure:  Multicenter, randomized, double- blind, placebo -controlled, parallel -group, single attack study; 
randomization to placebo, ubrogepant 25mg, or ubrogepant 50 mg .
Duration :  The study includes a screening period of up to 14 days prior to randomization, a 60 -day period in 
which to treat a single migraine attack, and a 4 -week follow -up period.
Study Treatment Groups :  Ubrogepant 25mg, ubrogepant 5 0 mg
Controls :  Ubrogepant placebo
Dosage/Dose Regimen :  Study participants will have up to 60 days to treat a single qualify ing migraine attack of 
moderate or severe headache pain intensity at home. Patients have the option to take a second dose of 
investigational product (IP) or rescue medication if the patient has either a nonresponding migraine or a 
migraine recurrence.  
  
 
 
 
 
 
 
Study Population Characteristics
Number of Patients :  Approximately 1650 patients will be randomized ( 550per treatment arm)
Condition/Disease :  Migraine with or without aura
Key Inclusion Criteria :  To be eligible for study participation, patients must be 18 to 75 years of age (inclusive), 
have a history of migraine with or w ithout aura for at least 1 year consistent with a diagnosis according to the 
International Classification of Headache Disorders criteria, 3rdedition, beta version ( ICHD -3 beta, 2013 ) and 
experience between 2 to 8 migraine attacks with moderate to severe headache pain in each of the 3 months prior 
to Screening (Visit 1) .
Key Exclusion Criteria :  
 UBR-MD-02
8

Allergan Confidential Protocol UBR -MD-02 Amendment 3
9Response Measures
Efficacy :  Rating of headache severity, absence or presence of migraine -associated symptoms, use of rescue 
medication, use of optional second dose, and recurrence of headache pain
 
 
 
 
 
General Statistical Methods a nd Types of Analyses:   The efficacy analyses will be based on the Modified 
Intent -to-treat ( mITT )Population. The last observation carried forw ard (LOCF) approach will be used to impute 
missing posttreatment values. Baseline for efficacy is defined as the last nonmissing efficacy assessment before 
the initial dose of study treatment. For each primary variable, the observed response proportions will be 
provided by treatment group. Theprimary efficacy variable of pain freedom at 2 hours after the initial dos ewill 
be analyzed using a logistic regression model with categorical terms for treatment group, historical triptan 
response (triptan responder, triptan insufficient responder, or triptan naïve), use of medication for migraine 
prevention (yes/no), and basel ine headache severity (moderate or severe). The primary efficacy variable of 
absence of the most bothersome symptom at 2 hours after the initial dose will be analyzed using a similar 
logistic regression model with an additional categorical term for the und erlying symptom that was identified as 
the most bothersome. The respective comparisons of the ubrogepant dose sversus placebo, which are the formal 
tests of the efficacy hypotheses, w ill be conducted using the appropriate pairw ise contrasts within the logi stic 
regression model. For secondary and other efficacy endpoints related to migraine headache pain severity and/or 
recurrence, migraine -associated symptoms, or use of rescue medication (including the second dose of IP), the 
observed response proportions w ill be analyzed using the same methods used to analyze the primary efficacy 
variables. For secondary efficacy endpoints on migraine -associated symptoms, baseline presence/absence of the 
symptom will be included as an additional covariate for the logistic r egression model .The proportion of 
patients reporting satisfaction with study medication at 2 and 24 hours after the initial dose, the proportion of 
patients able to function normally at 1, 2, 4, and 8 hours after the initial dose, and the proportion of pa tients 
assessed by the PGIC as “much better” or “very much better” at 2 hours after the initial dose will be analyzed 
using the same methods used to analyze the primary efficacy variables. The baseline functional disability score 
will also be included as a covariate for the analysis of the proportion of patients able to function normally. For 
the change from baseline in EQ- 5D-5Lindex value at 24hours after the initial dose
, treatment comparisons of 
ubrogepant dose groups versus placebo will be performed u sing an analysis of covariance (ANCOVA) model 
with categorical terms for treatment group, baseline severity, historical triptan response, and use of medication 
for migraine prevention, and with the baseline EQ-5D-5L index value as a covariate. Descriptive statistics will 
be provided for the change from baseline in the EQ VAS score at 24 hours after the initial dose by treatment 
group.
 
 
 
 
 
 
 
 
 UBR-MD-02
9

Allergan Confidential Protocol UBR -MD-02 Amendment 3
10 
 
 UBR-MD-02
10

Allergan Confidential Protocol UBR -MD-02 Amendment 3
11
 UBR-MD-02
11

Allergan Confidential Protocol UBR -MD-02 Amendment 3
12
 UBR-MD-02
12

Allergan Confidential Protocol UBR -MD-02 Amendment 3
13
 UBR-MD-02
13

Allergan Confidential Protocol UBR -MD-02 Amendment 3
14
 UBR-MD-02
14

Allergan Confidential Protocol UBR -MD-02 Amendment 3
151. Background and Clinical Rationale
What is Migraine and How Prevalent is It?
Migraine affects 18% of women and 6% of men in the United States with a peak prevalence 
occurring between the ages of 25 to 55 years. Approximately  one-third of migraineurs have 
3or more migraine headaches per month, and over half report severe impairment or the need 
for bed rest during an attack ( Lipton et al, 2007). In the U nited States , work loss due to 
migraine is estimated to cost ~ $13 billion annually ( Hu et al, 1999). P revalence is similar in 
Europe, with migraine headache affecting 17.6% of women and 8% of men 
(Stovner andAndree, 2010
).It is currently  ranked by  the W orld Health Organization as 19th 
among causes of disability  (Katsarava et al, 2012). 
Migraine is ty pically  characterized by  attacks of throbbing, unilateral headache of moderate 
or severe pain intensity , associated with nausea, vomiting, and/or sensitivity to light 
(photophobia) and sound (phono phobia). In about 25% of individuals, migraine headache 
may be preceded b y focal neurological dy sfunction (aura). Improving the diagnosis and 
optimizing treatments for migraine have been recognized as critically  important to reduce the 
global burden of 
migraine ( Katsarava et al, 2012
).
Because there are no biological markers for migraine, diagnosis is based on clinical history , 
exam, and the exclusion of other headache disorders. Phy sicians appl y clinical criteria to 
guide diagnoses and subsequent treatment. Episodic migraine is a s yndrome diagnosis 
applied to patients with migraine (with or without aura) who have 1 to 14 headache day s per 
month. Chronic migraine is a specific International Classification of Headache Disorde rs 
criteria, 3rdedition beta version (ICHD -3 beta) diagnosis applied to a subset of patients with 
≥15 headache day s per month ( ICHD-3 beta, 2013; Katsarava et al, 2012 ; 
Olesen etal,2006). 
What is CGRP  and What is its Relationship to Migraine?
CGR P(calcitonin gene-related peptide) isaneuropeptide implicated in
thepathoph ysiology 
ofmigraine. CGR Plevels inthe cranial venous outflow (ie, external jugular vein) are
increased durin g amigraine attack ( Goadsb y
 and Edvinsson, 1993) and exogenous ly
administered CGR Phasbeen shown to trigger migraine- likeheadache in migraineurs. The 
majorit y (80%to 90%) oftrigeminal Aδfibers thatinnervate thedura contain CGRP ,
suggesting that these fibers may be involved insterile neurogenic inflammation and
migraine pain transmission. Furthermore, the CGRP receptor is present on human meningeal
andcerebral blood vessels. These observations suggest that activation of the 
 UBR-MD-02
15
Allergan Confidential Protocol UBR -MD-02 Amendment 3
16trigeminovascular s ystem, with release of CGRP , may play  a key  role in migraine 
pathogenesis and that inhibition of CGRP function may yield anovel therapeutic approach to
treating migraine.
Establishment of CGRP  Antagonism to Treat Migraine
The abilit y of CGR Pantagonism torelieve pain inthe acute treatment of migraine was
established byusing anintravenous (I V)formulation ofolcegepant (Olesen etal,2004), 
andreplicated by Merck & Co.,Incwith anoral formulation oftelcagepant, ahighly
selective CGR Preceptor antagonist (CGRP RA). InPhase 3studie s,telcagepant was
superior to placebo inthe primary  endpoints of 2
-hour pain freedom, 2- hour pain relief, 
and the absence of associated symptom s(photophobia, phonophobia, andnausea), aswell as
thekey secondar y endpoint of 24-hour sustained pain freedom (Connor et al, 2009 ). 
Serum alanine aminotransferase (AL T) increases were observed with telcagepant as well as 
with a second CGRP  antagonist, MK- 3207. For this reason, the development of these 
compounds was stopped. 
What is Ubr ogepant?
Ubrogepant, a novel CGRP  receptor anta gonist that is chemicall y distinct from both 
telcagepant and MK -3207, is now being developed for the acute treatment of migraine. 
Preclinical and clinical studies conducted to date for ubrogepant have shown no evidence of 
hepa totoxicity .
A Phase 2b clinica l study was conducted, which compared 1 -, 10-, 25-, 50- , and 100
-mg 
doses of ubrogepant to placebo in the acute treatment of migraine. Overall, all the ubrogepant 
doses tested were well tolerated and t he adverse event (AE) profile of all ubrogepant doses 
did not dif fer significantly  from placebo. For the primary  efficacy  endpoint of pain freedom
at 2hours, ubrogepant doses of 1 and 10 mg did not dif fer from placebo, but doses of 25, 50, 
and 100 mg were better than placebo. For the primary  efficacy  endpoint of pain relief at 
2hours none of the ubrogepant doses dif fered from placebo , probabl y due to a high placebo 
response rate.
The a bsence of migraine -associated s ymptoms of photophobia, phonophobia, and nausea was
assessed as key  secondary  endpoints. Ubroge pant doses of 50 and 100 mg were significantly  
better than placebo for absence of phonophobia and photophobia at 2 hours, whereas 25 mg 
did not dif fer from placebo. None of the ubrogepant doses dif fered from placebo for the 
endpoint of absence of nausea at 2 hours. Measures of sustained migraine headache relief 
 UBR-MD-02
16
Allergan Confidential Protocol UBR -MD-02 Amendment 3
17(2to 24 hours and 2 to 48 hours sustained pain freedom and sustained pain relief) generally  
suggest edthat ubrogepant 50 mg and 100 mg were more effective than the 25 -mg dose.
The purpose of this study will be to assess the safety and ef ficacy  of 2 doses of ubrogepant, 
25and 50 mg, versus placebo in the acute treatment of migraine with or without aura, in a 
randomized, double -blind, placebo -controlled Phase 3 study .
2. Study Objectives and Clinical Hyp otheses 
2.1 Study Objectives
To evaluate the efficacy , safety , and tolerability  of 2 doses of ubrogepant ( 25and 50mg) 
compared to placebo for the acute treatment of a single migraine attack.
2.2 Clinical Hypotheses
1.At least 1 ubrogepant dose is superior to plac ebo in the acute treatment of migraine.
2.Ubrogepant is safe and tolerable.
3. Study Design
This multicenter , randomized, double -blind, placebo -controlled, parallel -group, single attack 
study  will enroll approximately  1650 patients from approximately  100 centers in the United 
States. Patients will be randomized (1:1:1) to 1 of the following 3 treatment groups:  placebo, 
ubrogepant 25 mg, or ubrogepant 50 mg.
Study  participants will have up to 60 day s to treat a single qualify ing migraine attack of 
moderate or severe intensity  at home. Patients unable to treat a qualify ing migraine within 
this time will be discontinued from the study .
 
 
 
 
 
 
The planned ef ficacy  assessments are rating of headache severity , 
absence or presence of 
migraine -associated s ymptoms, use of rescue medication, use of optional second dose ,and 
 UBR-MD-02
17

Allergan Confidential Protocol UBR -MD-02 Amendment 3
18recurrence of headache pain. A list and description of each efficacy  assessment is in 
Section 6.1 and the efficacy anal yses are presented in Section 7.3.1.
The planned safet y assessments are AEs, clinical laboratory  tests, electrocardiograms 
(ECGs), vital signs, ph ysical examination, and the Columbia -Suicide Severity  Rating Scale 
(C-SSRS). Details regarding safet y assessments are described in Section 6.5and t he safety  
analyses are presented in Section 7.3.3.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1 Adjudication Committee and 
Data Safety Monitoring Board
AnAdjudication Charter will be established and will describe the process for the blinded 
surveillance, monitoring, and adjudication b y the Clinical Adjudication Committee of events 
of posttreatment elevations of ALT and/or aspartate aminotransferase (AST) ≥ 3 times the 
upper limit of normal (ULN) in the ubrogepant program. The purpose of this committee 
charter will be to provide a standardized process for the adj udication of data associated with 
these events in order to determine whether the elevation was 
related to ubrogepant. 
 UBR-MD-02
18

Allergan Confidential Protocol UBR -MD-02 Amendment 3
19An independent Data Safety  Monitoring Board (DSMB) will also be established to review 
unblinded safet y data and summary reports, identify any safety issues and trends ,and make 
recommendations to the Sponsor , including modification or early  termination of a trial, if 
emerging data show unexpected and clinically significant AEs of treatment.
Details of the DSMB memberships, standard operational procedures for data 
monitoring/review , frequency  of review , and other pertinent details will be provided in a 
separate DSMB Charter .
4. Study Population and Entry Criteria
4.1 Number of Patients
Approximately  1650 patients will be randomized ( 550patients per arm) from approximately  
100 centers in the United States.
4.2 Study Population Characteristics
This study  will include adult patients with migraine with or without aura.
4.3 Inclusion Criteria
To be eligible to participate in the study , patients must meet the fol lowing criteria:
1.Written informed consent and patient privacy  information (eg, Written Authorization 
for Use and Release of Health and Research Stud y Information) obtained from the 
patient prior to initiation of an y study -specific procedures
2.Male or female patients ages 18 to 75 years, inclusive, at Visit 1
3.At least a 1 -year history  of migraine with or without aura consistent with a diagnosis 
according to 
the International Classification of Headache Disorders , 3rdedition, beta 
version ( ICHD -3beta, 2013; Section 12.1.1)
4.Migraine onset before age 50
5.By history , the patient’ s migraines t ypically last between 4 and 72 hou rs if untreated or 
treated unsuccessfull y and migraine episodes are separated b y at least 48 hours of 
headache pain freedom
6.History  of 2 to 8 migraine att acks per month with moderate to severe headache pain in 
each of the 3 months prior to Screening ( Visit1)
 
 UBR-MD-02
19

Allergan Confidential Protocol UBR -MD-02 Amendment 3
208.Be able to read, understand and complete the study  questionnaires and eDiary .
4.4 Exclusion Criteria
Patients who meet an y of the following criteria will not be eligible to participate in the study:
 
 
10. Dif ficult y distinguishing migraine headache from tension -type or other headaches. 
 
 
 
 
 
 
12.Has taken medication for acute treatment of headache (including acetaminophen, 
nonsteroidal anti- inflammatory  drugs [NSAI Ds], tr iptans, ergotamine, opioids, or 
combination analgesics) on 10 or more day s per month in any  of the 3 months prior to 
Visit 1. 
13.Has a history  of migraine aura with diplopia or impairment of level of consciousness , 
hemiplegic migraine, or retinal migraine as defined by  ICHD -3 beta (Section 12.1.1)
14.Has a current diagnosis of new persistent daily  headache, trigeminal autonomic 
cephalgia (eg, cluster headache), or painfu l cranial neuropathy  as defined by  
ICHD -3beta (Section 12.1.1
)
15. Required hospital treatment of a migraine attack 3 or more times in the 6 month s prior 
to Visit 1.
 
 
 
 UBR-MD-02
20

Allergan Confidential Protocol UBR -MD-02 Amendment 3
21 
 
17.Has a chronic non -headache pain condition requiring dail y pain medication (with the 
exception of pregabalin)
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
21

Allergan Confidential Protocol UBR -MD-02 Amendment 3
22 
 
 
 
 
 
 
 
28.History  of malignancy  in the 5 y ears prior to Visit 1, except for adequatel y treated 
basal cell or squamous cell skin can cer, or in situ cervical cancer
29.History  of any prior gastrointestinal (GI) conditions (eg, diarrhea s yndromes, 
inflammatory  bowel disease) that may  affect the absorption or metabolism of 
investigational product (IP); patients with prior gastric bariatric interventions ( eg, Lap 
Band )which have been reversed are not excluded
30.History  of acute hepatitis within 6 months ofScreening (Visit1) or chronic hepatitis 
(including nonalcoholic steatohe patitis) or apositive resulton anti -hepatitis A 
immunoglobulin M (IgM) antibody ,hepatitis Bsurface antigen, or anti –hepatitis C
antibodytesting at Screening (V isit 1)
 
 
 
 
 
 UBR-MD-02
22

Allergan Confidential Protocol UBR -MD-02 Amendment 3
23 
 
4.5 Permissible and Prohibited Medications/T reatments
4.5.1 Permissible Medications/T reatments
Medications which are not specificall y prohibited are allowed ; however, there may  be
clarifications a nd restrictions with certain medications.
The following medications are allowed during the study , but are prohibited within 48 hours 
prior to taking IP:
any triptan
any ergot derivative
any opioid
any NSAID
any other form of analgesic (including acetaminop hen)
any antiemetic agent
any proton pump inhibitor
The following medications are allowed during the study , but are prohibited within 24 hours 
prior 
to taking IP :
any antacid
any H2blocker
Examples of allowed but restricted medications listed above are display ed in 
Attachment 12.2.
Aspirin up to 325 mg/day  is allowed for cardiac prophy laxis.
Daily  use of pregabalin is allowed. 
 UBR-MD-02
23

Allergan Confidential Protocol UBR -MD-02 Amendment 3
24Selective serotonin reuptake i nhibitors (SSRI ) or serotonin norepinephrine reuptake 
inhibitors (SNRI ) will be permitted provided that treatment is stable for at least 60 day s prior 
to screening (Visit 1) and continues without change in dose throughout the study . SSRI s and 
SNRI s may  notbe started during the study .
Standard migra ine prophy lactic medications (e g, beta -blocker, tricy clic antidepressant, 
topiramate, valproic acid, botulinum toxin) will be permitted provided that the treatment is 
stable for at least 30 day s prior to Visit 1, and continues without change in dose throughout 
the study . Prophy lactic medications may  not be started during the study .
Therap y considered necessary  for the patient's welfare may  be given at the discretion of the 
investigator . If the permissibility  of a specific medication/treatment is in question, please 
contact Allergan.
4.5.1.1 AcuteTreatment / Rescue Medication
Medications for acute treatment of migraine listed above may  be taken during the study  
within the parameters noted in Section 4.5.1.  
 
 
 
 For details regarding the requirements for 
treatm ent with rescue medication and optional second dose, please refer to Section 5.6.3.
 
 
 
 
4.5.1.2 Definition of Females of (Non -)Childbearing Potential and/or 
Acceptable Contraceptive M ethods
For purposes of this study , females will be considered of childbearing potential unless they  
are naturall y postmenopausal 
(ie, no menses for 2 y ears) or permanently  sterilized 
(ie,bilateral tubal ligation , bilateral salpingectomy , bilateral oophore ctomy  orhysterectomy ). 
For women of childbearing potential who may  participate in the study , the following methods 
of contraception, if properly used, are generall y considered reliable: hormonal 
contraceptives (ie, oral, patch, vaginal ring, injection, implant), male condom with 
 UBR-MD-02
24

Allergan Confidential Protocol UBR -MD-02 Amendment 3
25intravaginal spermicide, diaphragm or cervical cap with spermicide, intrauterine device, 
vasectomized partner , or sexual abstinence.
For males who may  participate in the study , the following methods of contraception, if 
properl y used, are generally  considered reliable: post-bilateral vasectomy , barrier 
contraception, or sexual abstinence. Male participants must also refrain from donating sperm 
during the course of the study .
The investigator and each patient will determine the app ropriate method of contraception for 
the patient during the participation in the study .
If a female becomes pregnant during the stud y, the investigator will notify  Allergan 
immediately after the pregnancy  is confirmed and the patient will be exited from the study  
after appropriate safety  follow -up. The investigator will (1) notify the patient’ s phy sician that 
the patient was being treated with investigational drug ubrogepant, and (2) follow the 
progress of the pregnancy . The investigator must document the o utcome of the pregnancy  
and provide a cop y of the documentation to Allergan.
4.5.2 Prohibited Medications/T reatments
The following medications are prohibited 30 day s prior to Visit 1 and throughout the stud y 
period: 
strong and moderate cy tochrome P450 3A4 (CYP3A4) inhibitors, including but not 
limited to:  sy stemic (oral/I V) itraconazole, ketoconazole, fluconazole; erythromy cin, 
clarithrom ycin, telithromycin; diltiazem, verapamil; aprepitant ;cyclosporine ;
nefazodone ;cimetidine ;quinine ;and HIV  protease inhibi tors
strong and moderate CYP3A4 inducers, including but not limited to:  barbiturates 
(eg,phenobarbital and primidone), systemic (oral/IV) glucocorticoids, nevirapine, 
efavirenz, pioglitazone, carbamazepine, phen ytoin, rifampin, rifabutin, and St. John’ s 
wort
inhibitors of the BCRP  (breast cancer resistance protein) transporter (eg, rifampicin)
drugs with narrow therapeutic margins (eg, digoxin, warfarin)
Examples of prohibited medications in the classes noted above are displayed in Section 12.2.
The decision to administer a prohibited medication/treatment is done with the safet y of the 
study  participant as the primary  consideration. When possible, Allergan should be notified 
before the prohibited medication/treatment is administered.
 UBR-MD-02
25
Allergan Confidential Protocol UBR -MD-02 Amendment 3
264.5.3 Special Diet or Activities
Patients must refrain from consuming grapefruit or grapefruit juice from the time the consent 
form is signed until completion of the study . In addition, p atients will be asked to refrain 
from sleeping and consuming caf feine for at least 2 hours af ter they  take IP .
Alcohol intake should be limited to no more than 3 drinks per day  throughout the study . A 
drink is defined as a 12 -ounce can/bottle of beer , a 4-ounce glass of wine, o r 1ounce of 
liquor .
5. Study Treatments 
5.1 Study Treatments and Formulations
Ubrogepant  oral compressed tablets containing 25 mg of 
ubrogepant.
Ubrogepant  oral compressed tablets containing 50 mg of 
ubrogepant.
5.2 Control Treatment
Ubrogepant placebo (Formulation Number 1 1276X) tablets. 
5.3 Methods for Masking/Blinding
All study  treatments will be provided in identical blister cards to maintain masking of the 
study .Tablets of ubrogepant 25 mg, ubrogepant 5 0 mg, and placebo will be identical in 
appearance.
All patients will be instructed to take 1 tablet to treat their migraine attack regardless of the 
dose group to which they are assigned. The treatments to be used in this study are outlined in 
Table2.
5.4 Treatment Allocation Ratio
Patients who meet all of the study  entry  criteria will be randomized and provided with IPto 
treat 1 migrain e attack on an outpatient basis. Patients will be assigned randomly  in a 
1:1:1 ratio to 1 of the following 3 treatment groups:  placebo, ubrogepant 25 mg,or
ubrogepant 50 mg.
 UBR-MD-02
26

Allergan Confidential Protocol UBR -MD-02 Amendment 3
27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5 Method for Assignment to Treatment 
Groups/Randomization/
Prior to initiation of study  treatment, each patient who provides informed consent will be 
assigned a patient number that will serve as the patient identification number on all study  
documents.
 UBR-MD-02
27

Allergan Confidential Protocol UBR -MD-02 Amendment 3
28An automated interactive web response sy stem (IWRS) will be used to manage the 
randomization and treatment assignment. At the time of randomization (V isit 2), eligi ble 
patients will be randomly assigned to 1 of 3 treatment arms in a 1:1:1 ratio to placebo, 
ubrogepant 25 mg, or ubrogepant 50 mg  
 
Allergan Biostatistics (randomization programmer) will prepare the randomization codes. 
IPwill be labeled with medication kit numb ers. The I WRS will provide the site with the 
specific medication kit number(s) for each randomized patient at the time of randomization. 
Sites will dispense IPaccording to the IWRS instructions. Sites will receive the I WRS 
confirmation notifications for e ach transaction. All notifications are to be maintained with the 
study  source documents.
5.6 Treatment Regimen and Dosing
5.6.1 Treatment Administration
Table2presents the treatments that will be administered in this study . All patie nts will be 
instructed to take 1 tablet for their initial dose to treat their migraine attack regardless of the 
dose group to which they are assigned. If taking the optional second dose, patients will also 
be instructed to take 1 tablet.  
Table2 Treatments Adm inistered for Initial and Optional Second Dose
Drug/DoseRoute of 
AdministrationInvestigational 
Product
Administered for 
Initial Dose 
 
Placebo Oral (tablet) Placebo
Ubrogepant 25mg Oral (tablet) Ubrogepant 25mg  
Ubrogepant 50 mg Oral (tablet) Ubrogepant 50 mg
 
 
 UBR-MD-02
28

Allergan Confidential Protocol UBR -MD-02 Amendment 3
29 
 
 
5.6.3 Optional Second Dose and Rescue Medication
Two hou rs after initial treatment with IP, patients who did not adequatel y respond may  take a 
blinded optional second dose , active treatment or placebo ,as assign ed at the Randomization 
Visit(Visit 2 ) or patients’  own rescue medication, or may  elect to take no further medication. 
Inadequate response to the initial dose of IP is defined as meeting 1 of the following:
Continues to have a headache that is either moderate or severe; OR
After initial pain reli ef at 2 hours (defined as a headache severit y rating of no pain or 
mild pain), moderate or severe headache returns within 2 to 48 hours after the initial 
dose
 
 
 
 
 
 UBR-MD-02
29

Allergan Confidential Protocol UBR -MD-02 Amendment 3
30 
 
 
 
 
 
 
 
.
5.7 Storage of Investigational Product s/Treatments
IPat the site must be stored at room temperature in a secure ly locked cabinet. Further details 
regarding the storage of the IP  are in the Study  Reference Manual.
6. Response Measures and Summary of Data Collection Methods
6.1 EfficacyMeasures
Efficacy  measurement assessments are based on information recorded by the patient in an 
eDiary .
Rating of Headache Severity
Headache severit y will be subjectivel y rated b y the patient at predefined timepoints ( predose 
and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours after the initial dose ) on a scale from no pain to 
severe pain:
No pain
Mild pain
Moderate pain
Severe pain
Migraine Associated Symptoms
The patient will record whether the following associated s ymptoms were present or absent at 
predefined timepoints ( predose and 0.5, 1, 1.5, 2,3, 4, 6, 8, 24, and 48 hours after the initial 
dose):
 UBR-MD-02
30

Allergan Confidential Protocol UBR -MD-02 Amendment 3
31Photophobia
Phonophobia
Nausea
Vomiting
Use of Rescue Medication
Patients will record in their eDiary  any rescue medication taken within 48 hours after treating 
their migraine attack with IP,in addition documenting the date andtime that the rescue 
medication was taken.
Use of Optional Second Dose and Recurrence of Headache Pain
Patients will record in their eDiary  use of the optional second dose o f IPdue to inadequate 
response to their initial dose of IP. Date and time of the second dose will be reported, as well 
as pain severit y and absence or presence of migraine -associated s ymptoms at the time the 
second dose is taken and 2 hours after taking t he second dose. The incidence of recurrence in 
patients who had pain relief and pain freedom at 2 hours after the initial dose will be 
collected.
 
 
 
 
 
 
 
 
 
  
 UBR-MD-02
31

Allergan Confidential Protocol UBR -MD-02 Amendment 3
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
32

Allergan Confidential Protocol UBR -MD-02 Amendment 3
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
33

Allergan Confidential Protocol UBR -MD-02 Amendment 3
34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
34

Allergan Confidential Protocol UBR -MD-02 Amendment 3
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
35

Allergan Confidential Protocol UBR -MD-02 Amendment 3
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
36

Allergan Confidential Protocol UBR -MD-02 Amendment 3
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6 Other Study Supplies
The following will be provided by  Allergan :
All supplies needed for blood and urine sampling (central laboratory anal ysis, urine 
culture /sensitivity )and urine dipstick reagent strips
Shipping materials for shipment of laboratory  samples to central laboratory
All supplies needed for ECG assessment including ECG machine
Electronic diaries (eDiar y)
Electronic tablets (eT ablet)
 UBR-MD-02
37

Allergan Confidential Protocol UBR -MD-02 Amendment 3
386.7 Summary of Methods of Data Collection
An IWRS will be used to randomize patients and manage IPinventory .Data for this study  
will be collected using eCRFs via an electronic data capture s ystem, eDiaries, and eT ablets . 
Sourc e documents will be used at the sites and may  include a patient’ s medical record, 
hospital charts, clinic charts, the investigator ’s patient study  files, as well as the results of 
diagnostic tests such as laboratory  tests, ECGs, etc. Centralized vendors will be used for the 
analysis of all blood/urine samples and ECG assessments. Additional information on the 
collection and handling of samples is detailed in the respective laboratory  manuals.
Patients will use an eDiary to record details associated with the ir migraine attack, including, 
but not limited to the date and time of dosing, efficacy  assessments (eg, pain severit y, 
absence or presence of migraine -associated s ymptoms), and other important study  
information at designated timepoints post -dose. Training for the eDiary  will be provided for 
qualified patients during the Random ization V isit (Visit 2). For details regarding eDiary  
instructions to patients, see the eDiary  manual.
The C -SSRS will be conducted as a clinical interview at each visit and recorded by qualified
site staf f via an eT ablet.
7. Statistical Pr ocedures
7.1 Analysis Populations
7.1.1 Modified Intent -to-treat Population
The Modified Intent -to-treat (mITT) Population will consist of all randomized patients who 
received at least 1 dose of study  treatment, recorded a baseline migraine headache severity  
measurement, and had at least 1 postdose migraine headache severit y or migraine -associated 
symptom measurement at or before the 2- hour timepoint.
7.1.2 Safety Population
The Safet y Population will consist of all ran domized patients who received at least 1 dose of 
study  treatment.
 UBR-MD-02
38
Allergan Confidential Protocol UBR -MD-02 Amendment 3
397.2 Collection and Derivation of Efficacy Assessments
7.2.1 Primary Efficacy Variables
The coprimary  efficacy  parameters for the U nited States are as follows:  
Pain freedom (PF) at 2 hours after the initial dose , defined as a reduction in headache 
severit y from moderate/severe at baseline to no pain, at 2 hours after the initial dose
Absence of the most bothersome migraine -associated sy mptom (the most bothersome 
migraine -associated s ymptom will be ide ntified at baseline for each patient) at 2 hours 
after the initial dose . 
7.2.2 Secondary Efficacy Variables
The secondary  efficacy  parameters for theUnited Statesare:
Pain relief (PR) at 2 hours after the initial dose , defined as the reduction of a 
moderate/severe migraine headache to a mild headache or to no headache, at 2 hours 
after the initial dose
Sustained pain relief (SPR) from 2 to 24 hours after the initial dose , defined as pain 
relief with no administration of either rescue medication or the second dose of IP, and 
with no occurrence thereafter of a moderate/severe headache during the relevant 
number of hours after dosing with the IP
Sustained pain fr eedom (SPF) from 2 to 24 hours after the initial dose, defined as pain 
freedom with no administration of either rescue medication or the second dose of I P, 
and with no occurrence thereafter of a mild/moderate/severe headache during the 
relevant number of h ours after dosing with the IP
Absence of photophobia at 2 hours after the initial dose
Absence of phonophobia at 2 hours after the initial dose
Absence of nausea at 2 hours after the initial dose
 
 
 
 UBR-MD-02
39

Allergan Confidential Protocol UBR -MD-02 Amendment 3
40 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
40

Allergan Confidential Protocol UBR -MD-02 Amendment 3
41 
 
 
 
 
 
 
 
7.3 Hypothesis and Methods of Analysis
The efficacy anal yses will be based on the mITT  Population. The last -observation -carried -
forward (LOCF) approach will be used to impute missing posttreatment values. Baseline for 
efficac y is defined as the last nonmissing ef ficacy  assessment before the initial dose of study  
treatment. All statistical tests will be 2 -sided hy pothesis tests performed at the 5% level of 
significance for main ef fects. All confidence intervals will be 2-sided 95% confidence 
intervals, unless stated otherwise.
 UBR-MD-02
41

Allergan Confidential Protocol UBR -MD-02 Amendment 3
427.3.1 Efficacy Analyses
7.3.1.1 Primary Efficacy Analyses
For each primary  variable, the observed response proportions will be provided by  treatment 
group. The primary  efficacy  variable of pain freedom at 2 hours after the initial dose will be 
analyzed using a logistic regression model with categorical terms for treatment group, 
historical triptan response (triptan respon der, triptan insufficient responder, or triptan naïve), 
use of medication for migraine prevention (y es/no), and baseline headache severit y 
(moderate or severe). The primary  efficacy  variable of absence of the most bothersome 
symptom at 2 hours after the initial dose will be analy zed using a similar logistic regression 
model with an additional categorical term for the underly ing s ymptom that was identified as 
the most bothersome. If the logistic regression model fails to converge due to complete or 
quasi -complete separation, Firth’s penalized likelihood method ( Firth, 1993 ) will be used. 
The logistic regression model will be referred to as the primary  model. 
The respective comparisons of the ubrogepant dose sversus placebo, whi ch are the formal 
tests of the efficacy  hypotheses, will be conducted using the appropriate pairwise contrasts 
within the logistic regression model. Treatment comparisons will be based on the model -
derived odds ratios and their associated 95% confidence in tervals. Two- sided p -values will 
also be provided. 
, the study will be considered a success if at least 1 ubrogepant dose is 
demonstrated to be superior to placebo on both coprimary  variables after multiplicity  
adjustment. 
 
 
7.3.1.2 Secondary Efficacy Analyses 
For each secondary  efficacy  endpoint, the observed response propor tions will be analy zed 
using the same methods used to anal yze the primary  efficacy  variables. The respective 
comparisons of the ubrogepant doses versus placebo will be conducted using model -derived 
odds ratios, 95% confidence intervals and p -values from th e logistic regression model. For 
secondary  efficacy  endpoints on migraine -associated sy mptoms, baseline presence/absence 
of the sy mptom will be included as an additional covariate for the logistic regression model. 
 UBR-MD-02
42

Allergan Confidential Protocol UBR -MD-02 Amendment 3
43A graphical approach b y Bretz et al ( 2009 ) will be used to control the overall ty pe I error rate 
for multiple comparisons across the ubrogepant doses and the primary  and secondary  
efficacy  endpoints. The coprimary  efficacy  endpoints will serve as the gatekeepers of the 
secondary  endpoints. The secondary  endpoints will be tested in the same order as they  appear 
in the list of secondary  endpoints, except for the 3 migraine -associated s ymptoms which will 
be treated at the same level to allow the recy clingof weights am ong the 3 sy mptom 
endpoints. Recy clingof weights between the 2 doses is also allowed. The details of the 
multiple comparison procedure will be provided in the statistical analy sis plan (SAP).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
43

Allergan Confidential Protocol UBR -MD-02 Amendment 3
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
44

Allergan Confidential Protocol UBR -MD-02 Amendment 3
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
45

Allergan Confidential Protocol UBR -MD-02 Amendment 3
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
46

Allergan Confidential Protocol UBR -MD-02 Amendment 3
47 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
47

Allergan Confidential Protocol UBR -MD-02 Amendment 3
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
seline, all postbaseline (including non -PCS) values, and 
change from baseline.
 UBR-MD-02
48

Allergan Confidential Protocol UBR -MD-02 Amendment 3
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
49

Allergan Confidential Protocol UBR -MD-02 Amendment 3
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
50

Allergan Confidential Protocol UBR -MD-02 Amendment 3
51Table4 Assumed Response Rates and Estim ated Power for Primary and Secondary Efficacy 
Endpoints
EndpointAssumed Response 
Rate for PlaceboAssumed Response Rate for 
Ubrogepant GroupsPower After Multiplicity 
Adjustment
PF 2h 10% 24% >99%
Absence of the Most 
Bothersome Symptom 2h26.7% 37.7% 88%
PR 2h 34% 56% 88%
SPR 2 to 24h 19% 38% 88%
SPF 2 to 24h 6.5% 14.5% 83%
Absence of Photophobia 2h 32% 44% 78%
Absence of Phonophobia 2h 43% 57% 81%
Absence of Nausea 2h 59% 70% 71%
; h = hours; PF = pain freedom; PR = pain relief; SPF = sustained pain freedom; SPR = 
sustained pain relief
7.6 Interim Analyses
No interim anal ysis is planned for this study .
8. Patient Entry Procedures
8.1.1 Overview of Entry Procedures
Prospective patients as defined by  the inclusion and exclusion criteria in Sections 4.3and4.4
will be considered for entry  into this study .
8.1.2 Informed Consent and Patient Privacy
The study  will be discussed with the patient and a patient wishing to participate must give 
informed consent prior to any  study -related procedures or change in treatment. The patient 
must also give authorization and other written documentation in accordance with local 
 UBR-MD-02
51

Allergan Confidential Protocol UBR -MD-02 Amendment 3
52privacy  requirements (where applicable) prior to any  study -related procedures or change in 
treatment.
Each patient that provides informed consent will be assig ned a patient number that will be 
used on patient documentation throughout the study .
 
 
 
.
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
52

Allergan Confidential Protocol UBR -MD-02 Amendment 3
53 
 
 
 
 
 UBR-MD-02
53

Allergan Confidential Protocol UBR -MD-02 Amendment 3
54 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
54

Allergan Confidential Protocol UBR -MD-02 Amendment 3
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
aine-associated 
symptoms 2 hours after the second dose is taken
 UBR-MD-02
55

Allergan Confidential Protocol UBR -MD-02 Amendment 3
56
 
  
 
 
 
 
 
 
 
 
 
 UBR-MD-02
56

Allergan Confidential Protocol UBR -MD-02 Amendment 3
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
57

Allergan Confidential Protocol UBR -MD-02 Amendment 3
58 
 
 
 
8.5 Instructions for the Patients
Section 4.5.3 provides diet and act ivity instructions for patients enrolled in the study .
Patients will be provided with instructions on the use of the eDiary  to complete when they  
experience a qualify ing migraine . A practice session with a hy pothetical scenario should be 
administered to en sure the patients’  comprehension of the questions and the information to be 
entered . In addition, criteria for a qualify ing migraine to be treated as well as prohibited 
medications should be reviewed with the patients. Patients will be instructed to bring their 
eDiary  at the next clinic visit and return their IP  (used and unused).
 
8.6 Unscheduled Visits
Additional examinations and laboratory  assessments may  be performed as necessary  to 
ensure the safet y and well -being of the patients during the stud y period. Unscheduled visit 
eCRFs should be completed for each unscheduled visit. For all param eters not measured, 
indicate “not done”.
8.7 Compliance with Pr otocol
All assessments will be conducted at the appropriate visits as outlined in Table1, and th
e
timing of the visits should occur as close as possible to the specified day . At each visit, the 
patient will be asked if the patient changed the dose/regimen of any  existing concomitant 
 UBR-MD-02
58

Allergan Confidential Protocol UBR -MD-02 Amendment 3
59medications orinitiated the use of an y new concomitant medica tions since the last visit to 
ensure compliance with the protocol. 
Patients will record the requested information regarding their migraine attack and the IP  
taken in the eDiary . IPcompliance will be closel y monitored by  counting the number of 
tablets dispensed and returned. Every effort will be made to collect all unused IP.
8.8 Early Discontinuation of Patients
A premature discontinuation will occur when a patient who signed the informed consent form 
(ICF) and has been randomized ceases participation in the study , regardless of circumstances, 
before completion of the study . Patients can be prematurely  discontinued from the study  for 
one of the following reasons :
AE
Protocol violation
Noncompliance with IP
Withdrawal of consent (a clear reason must be documented)
Lost to follow -up. (Every ef fort must be made to contact the patient; a 
certified/traceable letter must be sent.)
Lack of Qualify ing Event (a qualify ing migraine is not treated within 60 day s from 
Randomization [Visit 2] )
Pregnancy
Other reasons
Patients may  voluntaril y withdraw from the stud y at an y time. Notification of earl y patient 
discontinuation from the study  and the reason for discontinuation will be clearl y documented 
on the appropriate electronic case report form (eCRF) . All randomized patients who 
prematurel y discontinue from the study, regardless of cause, should be seen for a final 
assessment. A final assessment will be defined as completion of the evaluations scheduled for 
Visit 3/Early  Termination  
.If 
the patient discontinues after IPis taken, the patient is also expected to return for the Safety 
Follow -up V isit (V isit 4) 4 weeks postdose.
 UBR-MD-02
59

Allergan Confidential Protocol UBR -MD-02 Amendment 3
608.9 Withdrawal Criteria
Women who become pregnant will be withdrawn from the study (see Section 4.5.1.2) and 
should refrain from taking IP. The patient should return to the clinic for early  termination
procedures (V isit 3) , including the safet y follow -up visit (V isit 4) if I P was taken.
Patients who reply  with “y es” to questions 4 or 5 in the suicidal ideation section or “y es” to 
any ques tion in the suicidal behavior section of the C -SSRS at Visit 3  
 and should receive appropriate follow -up as in routine clinical practice , 
including the safet y follow -up visit (V isit 4) if I P was taken.
A patient with a condition and/or a situation that, in the investigator's opinion, may  put the 
patient at significant risk, may  confound the study  results, or may  interfere significantl y with 
the patient's participation in the study  may  be withdrawn from treatment.
 
 
 
 
 
8.11 Study Termination
Allergan may stop the study (and/or the stud y site) for an y reason with appropriate 
notification.
9. Adverse Events
Adverse events occurring during the stud y will be recorded on an AEeCRF . If AEs occur , the 
first concern will be the safet y of the stud y participants.
9.1 Definitions
9.1.1 Adverse Event
An AEis an y untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and that does not necessarily  have a causal 
relationship with this treatment. An AEcan therefore be an y unfavorable and unintended sig n 
(including an abnormal laboratory  finding), s ymptom, or disease temporally  associated with 
 UBR-MD-02
60

Allergan Confidential Protocol UBR -MD-02 Amendment 3
61the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product. I n addition, during the screening period, AEs will be assessed 
regardless of the administration of a pharmaceutical product.
Note:  AEs must be collected once informed consent has been obtained, regardless of 
whether or not the patient has been administered study  drug.
Progression of treatment indicat ion including new or worsening of anticipated clinical signs 
or sy mptoms, which are collected as clinical efficacy  variables and assessed as unequivocall y 
associated with the disease progression and /or lack of efficacy , should NOT  be reported as 
AEs unles s the disease progression is greater than anticipated in the natural course of the 
disease. 
Adverse events will be assessed, documented, and recorded in the eCRF throughout the study  
(ie, after informed consent has been obtained). At each visit, the investigator will begin b y 
query ing for AEs by asking each patient a general, non -directed question such as “How have 
you been feeling since the last visit?” Directed questioning and examination will then be 
done as appropriate. All reported AEs will be documen ted on the appropriate eCRF .
9.1.2 Serious Adverse Event
An SAE is any  AEoccurring at an y dose that results in any  of the following outcomes:  death, 
a life -threatening adverse event, inpatient hospitalization or prolongation of existing 
hospitalization, a persi stent or significant disability/incapacity , or a congenital anomaly /birth 
defect. Important medical events that may not result in death, be life -threatening, or require 
hospitalization may  be considered a nSAE when, based upon appropriate medical judgment, 
they may  jeopardize the patient and may  require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. (See Section 9.3 for procedures for reporting 
SAEs .)
Allergan considers all cancer AEs as SAEs . In addition, Allergan considers any abortion 
(spontaneous or nonspontaneous) as a n SAE .
Preplanned surgeries or procedures for pre -existing, known medical conditions fo r which a 
patient requires hospitalization is not reportable as a n SAE .
Any preplanned surgery  or procedure should be clearl y documented in the site source 
documents by  the medically  qualified investigator at the time of the patient’ s entry  into the 
study .If it has not been documented at the time of the patient’ s entry  into the study , then it 
should be documented as a n SAE and reported to Allergan.
 UBR-MD-02
61
Allergan Confidential Protocol UBR -MD-02 Amendment 3
629.1.3 Severity
A clinical determination will be made of the intensity  of an adverse event. The severit y 
assessment for a clinical AEmust be completed using the following definitions as guidelines:
Mild Awareness of sign or s ymptom, but easily  tolerated
Moderate Discomfort enough to cause interference with usual activity
Severe Incapacitating with inability  to work or do usual activity
9.1.4 Relationship to Study Drug or Study Pr ocedure
A determination will be made of the relationship (if an y) between an AEand the study  drug 
or study  procedure, as applicable. A causal relationship is present if a determination is made 
that there is a reasonable possibility  that the AEmay have been caused by  the drug or study  
procedure.
9.2 Procedures for Reporting Adverse Events
Any AEmust be recorded on the appropriate eCRF .
All SAEs that are drug -related and unexpected (not listed as trea tment -related in the current 
investigator's brochure) must be reported to the governing Institutional Review 
Board/Independent Ethics Committee (I RB/IEC) as required by  the IRB/IEC, local 
regulations, and the governing health authorities. Any adverse event that is marked 
“ongoing” at the exit visit must be followed -up as appropriate.
9.3 Procedures for Reporting a Serious Adverse Event
Any SAE occurring during the stud y period (beginning with informed consent) and for at 
least 30 days after the last dose of study  drug must be immediately  reported but no later than 
24 hours after learning of a nSAE . Serious adverse events must be reported to Allergan or 
Agent of Allergan (eg, contract research organization [ CRO ]) and recorded on the SAE form. 
All patients with a nSAE must be followed up and the outcomes reported. The investigator 
must supply  Allergan and the I
RB/IEC with any  additional requested information (eg, 
autopsy  reports and discharge summaries).
In the event of a nSAE , the investigator must:
 UBR-MD-02
62
Allergan Confidential Protocol UBR -MD-02 Amendment 3
631.Notify  Allerga n immediately  by fax or email using the SAE form (contact details can 
be found on page 1 of the SAE form); phone numbers and relevant Allergan 
personnel contacts are also on the front page of protocol.
2. Obtain and maintain in his/her files all pertinent medical records, information, and 
medical judgments from colleagues who assisted in the treatment and follow -up of 
the patient.
3.Provide Allergan with a complete, written description of the AE(s) on the SAE form 
describing the event chronologically , including a ny treatment given (eg, medications 
administered, procedures performed) for the AE(s). Summarize relevant clinical 
information about the event:  signs, s ymptoms, diagnosis, clinical course and relevant 
clinical laboratory  tests, etc. Include any  additional or alternative explanation(s) for 
the causalit y which includes a statement as to whether the event was or was not 
related to the use of the investigational drug.
4.Promptly  inform the governing IRB/IEC of the SAE as required b y the IRB/IEC, local 
regulations , and the governing health authorities.
9.4 Exposure to Investigational Pr oductduring Pregnancy
Study  center personnel must report every  pregnancy  from the time he or she signs the ICF for 
the trial until 30 day safter the last dose of IPon the Pregnancy  Form as soon as possible 
(within 24 hours of learning of the pregnancy  to the SAE/P regnancy  fax number , 
even if no AE has occurred. Pregnancies in female partners of male patients 
must also be reported. The pregnancy must be followed to ter m and the outcome reported by  
completing a follow -up Pregnancy Form. If, however , the pregnancy  is associated with a 
SAE (eg, if the mother is hospitalized for hemorrhage), in addition to the Pregnancy  Form, a 
separate SAE Form must be filed as described i n Section 9.3with the appropriate serious 
criterion (eg, hospitalization) indicated.
 
 
 
 
 
 
 UBR-MD-02
63

Allergan Confidential Protocol UBR -MD-02 Amendment 3
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBR-MD-02
64

Allergan Confidential Protocol UBR -MD-02 Amendment 3
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.7 Procedures for Unmasking of Investigational Pr oduct
When necessary  for the safet y and proper treatment of the patient, the investigator can 
unmask the patient’ s treatment assignment to determine which treatment has been assigned 
and institute appropriate follow- up care. When possible, the Allergan Medical M onitor
should be notified prior to unmasking IP. The investigator should inform the Allergan 
Medical Monitor of the unmasking if there is no notification prior to the unmasking.
 UBR-MD-02
65

Allergan Confidential Protocol UBR -MD-02 Amendment 3
66The treatment assignment for the patient can be determined by designated site personnel 
logging on to the IWRS via password protected access. The reason for breaking the code 
must be recorded in the patient’ s source documents.
10. Administrative Items
This protocol is to be conducted in accordance with the applicable Good Clinical Pract ice 
(GCP) regulations and guidelines, eg, the ICH Guideline on GCP.
10.1 Protection of Human Patients
10.1.1 Compliance With Informed Consent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations
Written informed consent is to be obtained from each patient prior to any  study -related 
activities or procedures in the study , and/or from the patient's legall y authorized 
representative.
10.1.2 Compliance With IRB or IEC Regulations
This study  is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations. The investigator must obtain approval from a properl y 
constituted I RB/IEC prior to initiating the study  and re -approval or review at least annually . 
Allergan is to be notified immediately if the responsible I RB/IEC has been di squalified or if 
proceedings leading to disqualification have begun. Copies of all I RB/IEC correspondence 
with the investigator should be provided to Allergan.
10.1.3 Compliance With Good Clinical Practice
This protocol is to be conducted in accordance with the a pplicable GCP  regulations and 
guidelines.
10.1.4 Compliance With Electronic Records; Electr onic Signatures 
Regulations (US 21 CFR Part 1 1)
This study  is to be conducted in compliance with the regulations on electronic records and 
electronic signature.
10.2 Changes to the Protocol
The investigator must not implement any  deviation from or changes of the protocol without 
approval b y Allergan and prior review and documented approval/favorable opinion from the 
 UBR-MD-02
66
Allergan Confidential Protocol UBR -MD-02 Amendment 3
67IRB/IEC of a protocol amendment, except where necessary  to elimi nate immediate hazards 
to study  patients, or when the changes involve only logistical or administrative aspects of the 
study  (eg, change in monitors, change of telephone numbers).
10.3 Patient Confidentiality
A report of the results of this study  may  be publish ed or sent to the appropriate health 
authorities in any  country  in which the study  drug may  ultimatel y be marketed, but the 
patient’ s name will not be disclosed in these documents. The patient's name may  be disclosed 
to the sponsor of the study , Allergan, or the governing health authorities or the FDA  if they  
inspect the study  records. Appropriate precautions will be taken to maintain confidentiality  of 
medical records and personal information.
10.3.1 Patient Privacy
Written authorization and other documentation i n accordance with local privacy  requirements 
(where applicable) is to be obtained from each patient prior to enrollment into the study , 
and/or from the patient's legally  authorized representative in accordance with the applicable 
privacy  requirements (eg, HIPAA).
In accordance with HIP AA requirements, additional purposes of this study  may  include 
publishing of anon ymous patient data from the study .
10.4 Documentation
10.4.1 Source Documents
Source documents may  include a patient's medical records, hospital charts, clinic charts, the 
investigator's patient study files, the eDiary , as well as the results of diagnostic tests, such as 
laboratory  tests and ECG s. The investigator's cop y of the eCRF s serves as part of the 
investigator's record of a patient's stud y-related data.
The following information should be entered into the patient's medical record:
Patient’ s name
Patient’ s contact information
The date that the patient entered the stud y, patient number , and patient randomization 
(or medication kit) number
The study  title and/or the protocol number of the study  and the name of Allergan
 UBR-MD-02
67
Allergan Confidential Protocol UBR -MD-02 Amendment 3
68A statement that informed consent was obtained (including the date); a statement that 
written authorization or other local patient privacy  required documentation for this 
study  has been obtained (including the date)
Dates of all patient visits
Patient’ s medical history
Information regarding patient’ s diagnosis of migraine headache
All concurrent medications (l ist all prescription and nonprescription medications being 
taken at the time of enrollment; at each subsequent visit, changes to the list of 
medications should be recorded)
Occurrence and status of any  AE(s)
The date the patient exited the study , and a not ation as to whether the patient 
completed the study  or reason for discontinuation
The results of laboratory  tests performed b y the site (eg, results of urine pregnancy  
tests)
Key study  variables
Source documentation practices must follow Section 4.0 of I CHE6, Good Clinical Practice: 
Consolidated Guidance and ALCOA, ie, records must be attributable, l egible, 
contemporaneous, original, and accurate.
10.4.2 Electronic Case Report Form Completion
The investigator is responsible for ensuring that data are properly  recorded on each patient's 
eCRF and related documents. An investigator who has signed the protocol signature page 
should personally  sign for the 
eCRF (as indicated in the eCRF ) to ensure that the 
observations and findings are recorded on the eCRFscorrectl y and completely . The eCRFs 
are to be submitted to Allergan in a timel y manner at the completion of the study , or as 
otherwise specified b y Allergan and will be maintained in a central data repository .
10.4.3 Study Summary
An investigator's summary  will be provided t o Allergan within a short time after the 
completion of the study , or as designated b y Allergan. A summary  is also to be provided to 
the responsible IRB/IEC.
 UBR-MD-02
68
Allergan Confidential Protocol UBR -MD-02 Amendment 3
6910.4.4 Retention of Documentation
All study  related correspondence, patient records, consent forms, patien t privacy  
documentation, records of the distribution and use of all investigational products, and copies 
of eCRFs should be maintained on file.
For countries falling within the scope of the ICH guidelines, Allergan -specific essential 
documents should be ret ained until at least 2 y ears after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an I CH region or at least 2 y ears have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents 
should be retained for a longer period, however , if required b y the applicable regulatory 
requirement(s) or if needed by  the sponsor .
In addition, for countries not falling within the scope of the ICH guidelines, local regulatory  
requirements should be followed regarding the retention of clinical study  documentation.
Allergan requires that it be notified in writing if the investigator wishes to relinquish 
ownership of the data so that mutually  agreed -upon arrangements can be made for transfer of 
ownership to a suitably  qualified, responsible person.
10.5 Labeling, Pack aging, and Return or Disposal of Investigational 
Products/Treatments
10.5.1 Labeling/Pack aging
IPwill be supplied in blister cards and will be labelled with the protocol number , storage 
information, warning language, and instructions to take the tablets as directed. The card will 
also include the medication number . Immediately  before dispensing the blister card, the 
investigator or de signee will write the study  center number , patient’ s initials and patient
number , and date on the blister card.
10.5.2 Clinical Supply Inventory
The investigator must keep an accurate accounting of the number of investigational units 
received from Allergan, dispe nsed or administered to the patients, the number of units 
returned to the investigator by  the patient (if applicable), and the number of units returned to 
Allergan during and at the completion of the study . A detailed inventory  must be completed 
of all use d and unused IP and packaging . The IPmust be dispensed or administered only  by 
an appropriatel y qualified person to patients in the study . The medication is to be used in 
accordance with the protocol.
 UBR-MD-02
69
Allergan Confidential Protocol UBR -MD-02 Amendment 3
7010.5.3 Return or Disposal of Investigational Product s/Treatments 
and/or Supplies
All clinical IPs/treatments and/or supplies will be returned to Allergan or Aller gan designee 
for destruction.
10.6 Monitoring by the Sponsor
A representative of Allergan will monitor the study on a periodic basis. The determination of 
the e xtent and nature of monitoring will be based on considerations such as the objective, 
purpose, design, complexity , blinding, size, and endpoints of the study .
Authorized representatives of Allergan or regulatory authority representatives will conduct 
on-site visits to review , audit and copy  study -related documents. These representatives will 
meet with the investigator(s) and appropriate staf f at mutually  convenient times to discuss 
study -related data and questions.
10.7 Handling of Biological Specimens/Samples
Urine pregnancy  test kits will be provided by  the central lab; all urine pregnancy  testing will 
be administered on site according to instructions in the central lab manual. 
Samples of blood and urine for evaluation of hematology , blood chemistry , urinaly sis, 
coagulation, serology , and the urine drug screen will be analy zed at a centralized clinical 
laboratory  with certification from a recognized accreditation agency  (eg, College of 
American Pathology  [CAP] or Clinical L aboratory I mprovement Amendments [CLI A] 
certification).
 
 
 
All samples will be returned to Allergan or Allergan’ s designee for destruction. Allergan shall 
have full ownership rights to any  biological specimens/samples derived from the study .For 
additional details regarding handling of biological samples please refer to the Laboratory  
Manual.
 UBR-MD-02
70

Allergan Confidential Protocol UBR -MD-02 Amendment 3
7110.8 Publications
Allergan, as the sponsor , has proprietary  interest in this study . Authorship and manuscript 
composition will reflect joint cooperation between multiple investigato rs and sites and 
Allergan personnel. Authorship will be established prior to the writing of the manuscript. As 
this study  involves multiple centers, no individual publications will be allowed prior to 
completion of the final report of the multicenter study except as agreed with Allergan.
10.9 Coordinating Investigator
A signatory  Coordinating I nvestigator will be designated prior to the writing of the Clinical 
Study  Report.
 UBR-MD-02
71
Allergan Confidential Protocol UBR -MD-02 Amendment 3
7211. References
Bretz F , Maurer W, Brannath W , Posch M. A graphical approach to sequentially  rejective 
multiple test procedures. Stat Med. 2009;28:586 –604.
Cady  RK, McAllister PJ, Spierings ELH, Messina J, Carothers J, Djupesland PG, et al. A 
randomized, double -blind, placebo -controlled study  of breath powered nasal delivery  of 
sumatriptan powder (AVP-825) in the treatment of acute migraine (The T ARGET  Study ). 
Headache 2015;55:88 -100.
Connor KM,Shapiro RE,Diener HC, Lucas S
,Kost J,FanX,FeiK,Assaid C, Li nes C, Ho
TW. Randomized, controlled trial oftelcagepant for theacute treatment ofmigraine. 
Neurolog y. 2009 Sep 22;73(12):970-977.
Firth D. Bias reduction of maximum likelihood estimates. Biometrika.1993;80:27 –38.
Food and Drug Administration Guidance for Industry . Drug -Induced Liver Injury: 
Premarketing Clinical Evaluation ( UCM174090) July, 2009. 
http://www .fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf
Goadsb y PJ, Edvinsson L. The trigeminovascular system and migraine: studies 
characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann 
Neurol. 1993;33(1):4 8-
56.
Grund y SM, Cleeman J I, Bairey  Merz CN, Brewer Jr HB, Clark L T, Hunninghake DB, 
Pasternak RC, Smith Jr SC, and Stone N J. Implications of recent clinical trials for the 
National Cholesterol Education Program Adult T reatment Panel III Guidelines. J Am C oll of 
Cardiology . 2004;44:720 -732.
Hu XH, Markson LE,Lipton RB, Stewart WF,Berger ML. Burden ofmigraine inthe 
United States. Arch Intern Med. 1999;159:813 -818.
International Classification of Headache Disorders, 3rd edition (beta version). Headache 
Classification Committee of the International Headache Societ y (IHS). Cephalalgia. 
2013;33(9):629 –808. http://www.ihs -classification.org/_downloads/mixed/International -
Headache -Classification- III-ICHD -III-2013 -Beta.pdf
Katsarava Z, Buse DC, Mana ck AN, Lipt on RB. Defining the dif ferences between episodic 
migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86 -92.
 UBR-MD-02
72
Allergan Confidential Protocol UBR -MD-02 Amendment 3
73Lipton RB, Bigal ME, Diamond M, Freitag F , Reed MI , Stewart WF, on behalf of the AMPP  
advisory  group. Migraine prevalence, disease bur den, and the need for preventive therap y. 
Neurol. 2007;68(5):343 -349.
National Cholesterol Education Program Adult T reatment Panel III Guidelines. 
NIHPublication No. 01- 3670, May  2001. 
http://www .scymed.com/en/smnxdj/edzr/edzr9610.htm
Olesen J,Diene r H-
C, Husstedt IW, Goadsb yPJ,Hall D, Meie r U, et al.Calcitoni n
gene -related peptide receptor antagonist BIBN 4096 BSfortheacute treatment ofmigraine.
NEngl J Med. 2004;350(1 1):1104-1110.
Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby  PJ,et al. Headache 
Classification Committee. New appendix criteria open for a broader concept of chronic 
migraine. Cephalalgia. 2006;26(6):742-746.
Stovner L J, Andree C. Prevalence of headache in Europe: a review for the Eurolight Project. 
J Headache Pain. 2010;11:289 –299. 
http://www .ncbi.nlm.nih.gov/pmc/articles/PMC2917556/pdf/10194_2010_Article_217.pdf 
Accessed 05Apr2016
Tepper SJ, Cady  RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, et al. AVP-825 
breath -powered intranasal delivery  system containing 22 mg sumatriptan powder vs 100 mg 
oral sumatriptan in the acute treatment of migraines (The COMP ASS study ): a comparative 
randomized clinical trial across multiple attacks. Heada che. 2015 ;55(5 ):621-635.
09AUG2018 CSR UBR-MD-02
73
Allergan Confidential Protocol UBR -MD-02 Amendment 3
7412. Attachments
12.1 Examination Pr ocedures, Tests, Equipm ent, and Techniques
12.1.1 International Classification of Headache Disorders , 3rd Edition, 
Beta Version
09AUG2018 CSR UBR-MD-02
74
Allergan Confidential Protocol UBR -MD-02 Amendment 3
75
09AUG2018 CSR UBR-MD-02
75
Allergan Confidential Protocol UBR -MD-02 Amendment 3
76
09AUG2018 CSR UBR-MD-02
76
Allergan Confidential Protocol UBR -MD-02 Amendment 3
77
09AUG2018 CSR UBR-MD-02
77
Allergan Confidential Protocol UBR -MD-02 Amendment 3
78
09AUG2018 CSR UBR-MD-02
78
Allergan Confidential Protocol UBR -MD-02 Amendment 3
79
09AUG2018 CSR UBR-MD-02
79
Allergan Confidential Protocol UBR -MD-02 Amendment 3
80
09AUG2018 CSR UBR-MD-02
80
Allergan Confidential Protocol UBR -MD-02 Amendment 3
81
09AUG2018 CSR UBR-MD-02
81
Allergan Confidential Protocol UBR -MD-02 Amendment 3
82
09AUG2018 CSR UBR-MD-02
82
Allergan Confidential Protocol UBR -MD-02 Amendment 3
83
09AUG2018 CSR UBR-MD-02
83
Allergan Confidential Protocol UBR -MD-02 Amendment 3
84
09AUG2018 CSR UBR-MD-02
84
Allergan Confidential Protocol UBR -MD-02 Amendment 3
85
09AUG2018 CSR UBR-MD-02
85
Allergan Confidential Protocol UBR -MD-02 Amendment 3
86
09AUG2018 CSR UBR-MD-02
86
Allergan Confidential Protocol UBR -MD-02 Amendment 3
87
09AUG2018 CSR UBR-MD-02
87
Allergan Confidential Protocol UBR -MD-02 Amendment 3
88
09AUG2018 CSR UBR-MD-02
88
Allergan Confidential Protocol UBR -MD-02 Amendment 3
8912.2 Examples of Prohibited Medications
Prohibited Medications
The following medications are prohibited 30 day s prior to S creening and throughout the 
study  period:
Strong/Moderate CYP3A4 Inducers Strong/Moderate CYP3A4 Inhibitors
Antidepressant/ 
AntianxietyBarbiturates 
Amobarbital (Amytal®)
Aprobarbital (Alurate®)
Butalbital (Fiorinal®, 
Fioricet®)
Butabarbital (Busodium®, 
Butisol®)
Mephobarbital (Mebaral®)
Pentobarbital (Nembutal®)
Phenobarbital (Luminal®,
Solfoton®)
Secobarbital (Seconal®)Nefazodone (Serzone®)
Antiseizure Carbamazepine (Atretol®, Carbatrol®, 
Epitol®, Equetro®, Tegretol®)
Oxcarbazepine (Trileptal®)
Phenytoin (Dilantin®, Phenytek®)
Primidone (Myidone®, Mysoline®)
Diabetes Pioglitazone (Actos®)
Troglitazone (Rezulin ®, Resulin®)
Antiemetic Aprepitant (Emend®)
Antihypertension Diltiazem (Cardizem®)
Verapamil (Calan®, Calan SR®)
Glucocorticoid
(Systemic)Betam ethasone (Celestone®)
Dexamethasone (Baycadron®, 
DexPak®)
Hydrocortisone (Cortef®)
Methylprednisolone (Medrol®)
Prednisolone (Prelone®)
Prednisone (Deltasone®)
Triamcinolone (Kenalog®)
Antibiotics Rifabutin (Mycobutin®) 
Rifampicin/ Rifampin (Rifadin®, Rifater®, 
Rimactane®) Erythromycin ( Benzamycin®, EryTab®)
Clarithromycin (Biaxin®)
Telithromycin (Ketek®)
Antifungal Fluconazole (Diflucan®, Trican®)
Itraconazole (Sporanox®)
Ketoconazole (Nizoral®)
Anti-HIV Efavirenz (Stocrin®, Sustiva®) 
Nevirapine (Viramune®)Indinavir (Crixivan®)
Nelfinavir (Viracept®) 
Ritonavir (Norvir®)
Saquinavir (Fortovase®, Invirase®)
Immunosuppressant Cyclosporine - o ral/IV only (Neoral®,
Sandimmune®)
Other St John’s Wort
Enzalutamide (Xtandi®)
Modafinil (Provigil®)Buprenorphine (Cizol®, Subutex®, 
Suboxone®), Quinine, armodafinil 
(Nuvigil TM)
09AUG2018 CSR UBR-MD-02
89
Allergan Confidential Protocol UBR -MD-02 Amendment 3
90Drugs with Narrow Therapeutic Margins Warfarin (Coumadin®)
Digoxin (Digitek®, Lanoxin®, Digox®)
Cisapride (Prepulsid®, Propulsid®)
Pimozide (Orap®)
The following medications are allowed during the study ; however , they  areprohibited within 
48 hours prior to taking IP:
Triptan Almotriptan (Axert®)
Eletript an (Relpax®)
Frovatriptan (Frova®)
Naratrip tan(Amerge®)
Rizatrip tan(Maxalt®)
Sumatriptan (Imitre x®) 
Zolmitript an(Zomig®)
Ergot Derivative Dihydroergotamine (DHE 45®, Migranal®)
Ergotamine (Cafergot®, Ergomar®, Wigraine®)
Opioid Tram adol (eg, Ultracet®, Ultram®)
Butorphanol (Stadol®)
Codeine -containing analgesics (eg, Tylenol with Codeine #3®)
Hydrocodone (Zohydro ER™ )/Hydrocodone- containing analgesics (eg, 
Vicodin®)
Oxycodone (Oxycontin®, Roxicodone®)/Oxycodone -containing 
analgesics (eg, Percocet®) 
Morphine (MS Contin®)
NSAID Aspirin 
Com bination medicines with NSAID s(eg, Excedrin®)
Diclofenac (Arthrotec®, Cataflam®, Voltaren®)
Ibuprofen (eg, Advil®, Excedrin IB®, Motrin®)
Ketoprofen (eg, Orudis®) 
Naproxen (eg, Aleve®, Naprosyn®)
Analgesic Acetaminophen (eg, Tylenol®or any combination drug Tylenol®)
Antiemetic agent Chlorpromazine (Thorazine®)
Hydroxyzine (Vistaril®)
Metoclopramide (Reglan®)
Ondansetron (Zofran®)
Prochlorperazine (Compazine®)
Prom ethazine (Phenergan®, Mepergan®)
Proton Pum p Inhibitor Esomeprazole (Nexium®)
Lansoprazole (Prevacid®, Zoton®)
Omeprazole (Losec®, Prilosec®, Zegerid®)
Pantoprazole (Pantoloc®, Pantozol®, Protonix®, Somac®, Zurcal®)
Rabeprazole (Aciphex®, Pariet®, Rabecid®)
09AUG2018 CSR UBR-MD-02
90
Allergan Confidential Protocol UBR -MD-02 Amendment 3
91The following medications are allowed during the study ; however , they  areprohibited within 
24 hours prior to taking IP:
Antacid Aluminum Carbonate Gel (Basaljel®)
Aluminium Hydroxide (AlternaGEL®, Amphojel®)
Aluminium Hydroxide and magnesium hydroxide (Maalox®, Mylanta®)
Bismuth Subsalicylate (Pepto -bismol®)
Calcium Carbonate (Alcalak®, Quick- Eze®, Rennie®, Rolaids®, Titralac®, TUMS®)
Hydrotalcite (Talcid®)
Magaldrate plus Simethicone (Pepsil®)
Magnesium Hydroxide (Phillips' Milk of Magnesia®)
Sodium Bicarbonate (Alka -Seltzer®, Bicarbonate of Soda®)
H2Blocker Famotidine (Pepcid®)
Nizatidine (Axid®)
Ranitidine (Zantac®)
Cimetidine (Tagamet®) 
09AUG2018 CSR UBR-MD-02
91
Allergan Confidential Protocol UBR -MD-02 Amendment 3
9212.3 Glossary of Abbreviations
Term/Abbr eviation Definition
AE adverse event
ALCOA attributable, legible, contemporaneous, original, and a ccurate
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOV A analysis of covariance
AST aspartate aminotransferase
BCRP breast cancer resistance protein
BP blood pressure
C2hr plasma concentration at 2 hours postdose
CAP College of American Pathology
CFR Code of Federal Regulations
CGRP calcitonin gene -related peptide
CGRP  RA CGRP  receptor antagonist
CHD coronary  heart disease
CLIA Clinical L aboratory  Improvement Amendments
CRO contract research organization
C-SSRS Columbia -Suicide Severity  Rating Scale
CV cardiovascular
CYP3A4 cytochrome P450 3A4
DBS dry blood spot
DSMB Data Safet y Monitoring Board
EC 50 half-maximal ef fective concentration
ECG electrocardiogram
eCRF electronic case report form
eDiary electronic diary
eDISH evaluation of drug- induced serious hepatotoxicity
EMA European Medicines Agency
Emax maximum drug ef fect
EQ-5D- 5L European Quality  of Life – 5-Dimensional – 5- Level 
eTablet electronic tablet
EU European Union
FDA US Food and Drug Administration
FDS Functional Disability  Scale
GCP Good Clinical Practices
HIPAA Health Insurance Portability  and Accountability  Act
HIV Human immunodeficiency virus
09AUG2018 CSR UBR-MD-02
92
Allergan Confidential Protocol UBR -MD-02 Amendment 3
93ICF informed consent form
ICH International C ouncil on Harmonisation
ICHD -3 beta International Classification of Headache Disorders criteria, 3rd
edition (beta version, 2013)
IEC Independent Ethics Committee
IETD investigator emergency treatment disclosure
IgM immunoglobulin M
INR international normalized ratio (blood -clotting test)
IP investigational product
IRB Institutional Review Board
IV intravenous
IWRS interactive web response sy stem
LOCF last observation carried forward
mITT Modified Intent -to-treat
NCEP National Cholesterol Education Program
NSAID nonsteroidal anti- inflammatory  drug
PCS potentially  clinicall y significant
PF pain freedom
PGIC Patient Global I mpression of Change
PR pain relief
QTc QT interval corrected for heart rate
QTcF QT interval corrected for heart rate using the Fridericia formula 
(QTcF = QT/(RR)⅓)
SAE serious adverse event
SAP statistical analy sisplan
SSRI selective serotonin reuptake inhibitors
SNRI serotonin norepinephrine reuptake inhibitors
SPF sustained pain freedom
SPR sustained pain relief
TBL total bilirubin
TEAE treatment -emergent adverse event
ULN upper limit of normal
US United States
VAS visual analogue scale
09AUG2018 CSR UBR-MD-02
93

Allergan Confidential Protocol UBR -MD-02 Amendment 3
9412.4 Protocol Amendment 1 Summary
Title:  A Phase 3, Multicenter , Randomized, Double -blind, Placebo -controlled, Single Attack 
Study  to Evaluate the Ef ficacy , Safety , and Tolerability  of Oral Ubrogepant in the Acute 
Treatment of Migraine
Protocol UBR -MD-02Amendment 1
Date of Amendment:  09 June 2016
Amendment Summary
This summary  includes changes made to Protocol UBR -MD-02 (19 May  2016). This 
protocol was amended to:  1) revise title page, key responder definitions, health outcomes 
measures, and efficacy variables, and 2) clarify  various study  activities.
Following is a summary  of content -oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes. Minor editorial and document for matting 
revisions have not been summarized.
Section Revision Rationale
Protocol Title Page Revised name of the Authorized 
US Agent from Allergan, Inc. to 
Allergan Sales, LLCThe name of Allergan in the US has 
changed
Added Emergency Telephone 
NumberTo remove need to consult the study 
contacts page
Added “Protocol Amendment 1 
Date” to the title pageTo reflect the approval date of 
Amendment 1
Deleted Name and contact 
information of Allergan study 
personnel andTo reflect change in study contacts 
page
Protocol Summary,  
 
 
  
09AUG2018 CSR UBR-MD-02
94

Allergan Confidential Protocol UBR -MD-02 Amendment 3
95Section Revision Rationale
 
 
Section 3.1, 
Adjudication 
Committee and Drug 
Safety Monitoring 
BoardAdded Drug to title and text for 
DSMB, and a dded that details of 
the DSMB will be provided in a 
separate CharterClarification
  
 
Section 4.5.1.2, 
Definition of Females 
of (Non-) Childbearing 
Potential and/or 
Acceptable 
Contraceptive MethodsAdded to description of male 
contraception methods:  Male 
participants should also refrain 
from donating sperm during the 
course of the study.To clarify that since male study 
participants should use contraception 
during the study, they should also 
refrain from donating sperm per central 
IRB request
 
   
 
Section 6.2, Health   
  
 
  
 
  
 
 
  
 
 
 
  
 
  
  
 
   
 
  
 
09AUG2018 CSR UBR-MD-02
95

Allergan Confidential Protocol UBR -MD-02 Amendment 3
96 
 
 
 
  
 
  
   
 
09AUG2018 CSR UBR-MD-02
96

Allergan Confidential Protocol UBR -MD-02 Amendment 3
9712.5 Protocol Amendment 2 Summary
Title:  A Phase 3, Multicenter , Randomized, Double -blind, Plac ebo-controlled, Single Attack 
Study  to Evaluate the Ef ficacy , Safety , and Tolerability  of Oral Ubrogepant in the Acute 
Treatment of Migraine
Protocol UBR -MD-02 Amendment 2
Date of Amendment:  04 Nov 2016
Amendment Summary
This summary  includes changes made to Protocol UBR -MD-02 Amendment 1 (09 Jun2016). 
This protocol was amended to : 1) update health outcomes measures and ef ficacy  variables; 
and 2) clarify  several exclusion criteria
Following is a summary  of content -oriente d changes that were made to each section of the 
protocol, and a brief rationale for these changes. Minor editorial and document formatting 
revisions have not been summarized.
Section Revision Rationale
Global Change In reference to the Satisfaction With Study 
Medication assessment, instances of 
“migraine treatment” were changed to 
“study medication”Based on input from patient qualitative 
interviews, expert panel suggested 
rephrasing “migraine treatment” to 
“study medication ”
Global Change Revised SAE/Pr egnancy Reporting Fax 
Number Administrative update
Protocol Title Page  Administrative update
Protocol Summary –
General Statistical 
Methods and Types of 
AnalysesRevised to note that PGIC will be 
completed 2 hours after the initial dose: 
…the proportion of patients assessed by 
the PGIC as “much better” or “very much 
better” at 224hours after the initial dose 
will be analyzed using the same methods 
used to analyz e the primary efficacy 
variables.Expert input recommended a change in 
PGIC assessment from 24 hours to 2 
hours after the initial dose to increase 
the probability of differentiating 
betw een treatment and placebo
  
09AUG2018 CSR UBR-MD-02
97

Allergan Confidential Protocol UBR -MD-02 Amendment 3
98Section Revision Rationale
  
 
  
 
 
 
 
 
 
 
  
 
Section 3.1, 
Adjudication 
Committee and Data 
Safety Monitoring 
BoardSection title and in -text change updated to 
“Data Drug Safety Monitoring Board” Clarification
Section 4.4,  
 
 
 
  
 
 
 
 
Section 4.4,  
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 4.4,  
09AUG2018 CSR UBR-MD-02
98

Allergan Confidential Protocol UBR -MD-02 Amendment 3
99Section Revision Rationale
Section 4.4, 
Exclusion Criterion 21History of gastric or small intestinal 
surgery (including gastric bypass surgery 
or banding), or has a disease that causes 
malabsorption (eg, Crohn’s disease) any 
prior gastrointestinal (GI) conditions (eg, 
diarrhea syndromes, inflammatory bowel 
disease) that may affect the absorption or 
metabolism of investigational product (IP); 
patients with prior gastric bariatric 
interventions (eg, Lap Band )which have 
been reversed are not excludedClarification on excluded GI 
procedures and conditions including 
inclusion of patients with reversal of 
certain procedures.
Section 4.4,  
 
 
 
 
 
Section 4.5.1 ,
Perm issible 
Medications/TreatmentsDeleted “any proton pump inhibitor” from
list of medications prohibited within 24
hours prior to taking IP and added it to list 
of medications prohibited within 48 hours 
prior to IP dosingAmended per FDA request
Section 4.5.1.2 ,
Definition of Females 
of (Non -) Childbearing 
Potential and/or 
Acceptable 
Contraceptive MethodsMoved surgical sterilization from a method 
of contraception to defining women of 
child -bearing potential :
For purposes of this study, females will be 
considered of childbearing potential unless 
they are naturally postmenopausal (ie, no 
menses for 2 years) or permanently 
sterilized (ie, bilateral tubal ligation ,
bilateral salpingectomy, bilateral 
oophorectomy orhysterectomy).Clarification
09AUG2018 CSR UBR-MD-02
99

Allergan Confidential Protocol UBR -MD-02 Amendment 3
100Section Revision Rationale
Section 4.5.1.2 ,
Definition of Females 
of (Non -) Childbearing 
Potential and/or 
Acceptable 
Contraceptive MethodsUpdated acceptable contraceptive 
methods:
For w omen of childbearing potential who 
may participate in the study, the following 
methods of contraception, if properly used, 
are generally considered reliable:
horm onal contraceptives (ie, oral, patch, 
vaginal ring, injection, implant), male 
condom with intravaginal spermicide, 
diaphragm or cervical cap with 
spermicide, vaginal contraceptive ring, 
intrauterine device, surgical sterilization 
(bilateral tubal ligation, bilateral 
salpingectomy), vasectomized partner, or 
sexual abstinence ….. Male participants 
should must also refrain from donating 
sperm during the course of t he study .Clarification
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
  
 
 
 
09AUG2018 CSR UBR-MD-02
100

Allergan Confidential Protocol UBR -MD-02 Amendment 3
101Section Revision Rationale
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
  
 
  
 
 
 
  
 
 
 
  
 
  
09AUG2018 CSR UBR-MD-02
101

Allergan Confidential Protocol UBR -MD-02 Amendment 3
102Section Revision Rationale
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Section 12.2,
Examples of Prohibited 
MedicationsAdded “(Systemic) ” to Glucocorticoid 
classClarification that only systemic 
glucocorticoids are excluded
Deleted the following Proton Pump 
Inhib itors from the list of medications 
prohibited w ithin 24hours prior to IP 
dosing and added them to the list of 
medications prohibited w ithin 48 hours 
prior to IP dosing:
Esom eprazole (Nexium®)
Lansoprazole (Prevacid®, Zoton®)
Omeprazole (Losec®, Prilosec®, Zegerid®)
Pantoprazole (Pantoloc®, Pantozol®, 
Protonix®, Som ac®, Zurcal®)
Rabeprazole (Aciphex®, Pariet®, 
Rabecid®)Amended per FDA request
Added to “Others” category: armodafinil 
(NuvigilTM)Clarification
09AUG2018 CSR UBR-MD-02
102

Allergan Confidential Protocol UBR -MD-02 Amendment 3
10312.6 Protocol Amendment 3 Summary
Title:  A Phase 3, Multicenter , Randomized, Double- blind, Placebo -controlled Single Attack 
Study  to Evaluate the Ef ficacy , Safety , and Tolerability  of Oral Ubrogepant in the Acute 
Treatment of Migraine
Protocol UBR -MD-02 Amendment 3
Date of Amendment:  19May 2017
Amendment Summary
This summary  includes changes made to Protocol UBR -MD-02 Amendment 2, 
(04Nov 2016). This protocol was amended to: 1) increase sample size from 450 to 
550
patients per arm ; 2) revise statistical methods to include an additional categorical term to 
the logistic regression analy sis for t he primary  efficacy  variable of absence of the most 
bothersome s ymptom at 2 hours after the initial dose ; 3) 
revise statistical methods to include 
an additional categorical term to the logistic regr ession analy sisfor the secondary  efficacy  
endpoints on migraine -associated s ymptoms; 4) reorder the secondary  endpoints,  
 
and6) remove the 35% triptan insufficient responder 
requirement .
Following is a summary  of content -oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes. Minor editorial and document formatting 
revis ions have not been summarized.
Section Revision Rationale
Title Page Replaced Emergency Telephone Number and 
Allergan Medical Monitor Contact Information 
with instructions to refer to Study Contacts 
Sheet.Administrative update
Protocol Summary, 
Section 3 Study Design, 
Section 4.1 Number of 
PatientsIncreased number of patients to be randomized 
to approximately 1650 (550 patients per 
treatment arm).Sample size re -estimate based 
on updated assumptions
09AUG2018 CSR UBR-MD-02
103

Allergan Confidential Protocol UBR -MD-02 Amendment 3
104Section Revision Rationale
Section 5.5 Method for 
Assignment to Treatmen t
Groups/Randomization/Removed requirement that at least 35% of 
  
 
 
Section 7.2.2 Secondary 
Efficacy Variable
  
 
 
 
 
Protocol Summary, 
Section 7.3.1.1 Primary 
Efficacy AnalysesRevised logistic regression model as follows:
For each primary variable, the observed 
response proportions w ill be provided by 
treatment group. The primary eff icacy variable 
of pain freedom at 2 hours after the initial dose 
will be analyzed using a logistic regression 
model with categorical terms for treatment 
group, historical triptan response (triptan 
responder, triptan insufficient responder, or 
triptan naïve ), use of medication for migraine 
prevention (yes/no), and baseline headache 
severity (moderate or severe). The primary 
efficacy variable of absence of the most 
bothersome symptom at 2 hours after the initial 
dose w ill be analyzed using a similar logistic 
regression model with an additional categorical 
term for the underlying symptom that was 
identified as the most bothersome. The treatment response on the 
most bothersome symptom 
varies according to which 
symptom is identified as the 
most bothersome
Protocol Summary, 
Section 7.3.1.2 Secondary 
Efficacy AnalysesRevised logistic regression model to include:
For secondary efficacy endpoints on migraine -
associated symptoms, baseline presence/absence 
of the symptom will be included as an additional 
covariate for the logistic regression model.The treatment response on 
migraine -associated symptoms 
is different depending on 
whether the patient had the 
symptom at predose baseline 
09AUG2018 CSR UBR-MD-02
104

Allergan Confidential Protocol UBR -MD-02 Amendment 3
105Section Revision Rationale
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
09AUG2018 CSR UBR-MD-02
105
